Blog

The fund’s portfolio division comprises three segments: long-term holdings (60%), power trading positions (10%), and cash (30%). Our high cash position enables us to capture opportunities as they arise. We will deploy much more cash during a bear market to take advantage of deep bargain opportunities. Conversely, we will increase our cash position in a...

Our fund’s stock-picking process involves an integrated assessment of clinical-stage biotech companies, focusing on the lead drug or “Crown Jewel” of the pipeline. This includes evaluating the drug’s Mechanism of Action, Disease Context, and forecasting its chances of passing through clinical studies and gaining FDA approval. It’s important to have a deep understanding of how...

Aligned with Warren Buffett’s wisdom, we are patient with our investments to capture the most upsides. This entails holding stakes in companies for manyyears from their preclinical/clinical phases to early product launch. At that point, we would usually take partial profits to generate more capital and minimize risks while leaving a portion of the shares...

Similar to Warren Buffet, our fund approaches stock buying as investing in a piece of a wonderful business. As such, we would acquire mostly long positions for our investment. There are more upsides to going long while having limited risks. By going long, there is a potential to gain multiple folds on an investment. In...

Our deep specialization in life science equity confers sector expertise and thereby positions us to outperform in this niche. Taking specialization to the next level, we concentrate our investment on the “growth biotech” stocks category. This allows us to capture the tremendous upsides in clinical stage and early product bioequities. Growth stocks tend to outperform...

To boost our gains, we leverage our expert edge in the forecasting of biotech binary events outcomes. As important catalytic developments for clinical stage biotech companies, these events entail either an FDA approval and significant clinical data report. Whenever a drug either passes through a major clinical hurdle or gains FDA approval, their stock is...

Known as Integrated BioSci Investing, our investment practice is inspired by various gurus, including Peter Lynch, Warren Buffett, Phillip Fisher, and Ben Graham. We integrate what we learned from those luminaries with various disciplines (i.e., medical, scientific, and market expertise) that are adapted specifically to biotech investing like a custom-made suit. In our approach, we...